1 November 2024 in Molecular Pharmaceutics
17 February 2026 in European Journal of Pharmaceutics and Biopharmaceutics
Evaluation of pharmacokinetics is a cornerstone in the developability assessment of therapeutic monoclonal antibodies (mAbs). For accurate evaluation of mAbs' concentration-time profile, administered mAbs should be isolated from the interfering host proteins in serum samples. While there are multiple approaches to purify and quantify the administered mAb, they are limited by drawbacks such as low specificity, relatively-large plasma volume requirements, and tedious procedures for sample preparation and analysis. Here, we present an immunoprecipitation assay that uses a highly specific anti-human IgG1 antibody coupled with magnetic beads (R10-coupled Dynabeads) for the purification of adalimumab and forced-oxidized variants. The specificity and binding capacity of R10-coupled Dynabeads were confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. To demonstrate the wide applicability of this method, two different stressed variants involving mixtures with rat proteins were examined which are chemical oxidation stress and physical agitation stress. The results showed comparable recovery of native adalimumab and oxidized variants from in vitro and in vivo rat proteins mixture. R10-coupled Dynabeads also recovered aggregated species, but the method itself induced more aggregate formation as evident from analysis by dynamic light scattering and background membrane imaging. Pharmacokinetic evaluation showed a typical concentration-time profile for native adalimumab which is broadly consistent with reported profiles. This method can provide an efficient and highly-specific recovery of human IgG1 and degradation products from preclinical biological samples, provided that the epitope recognized by the used anti-human IgG antibody is retained and accessible. Furthermore, the integration of R10-coupled Dynabeads purification, Trypsin/Lys-C digestion, and QToF LC-MS/MS analysis enabled efficient capture of the oxidized species generated by AAPH and H2O2 (% sequence coverage ≥ 90%). Accordingly, this combined workflow can be applied to study in vivo modifications of therapeutic proteins (e.g. oxidation, deamidation) after exposure to an anatomical environment.
28 November 2025 in Journal of Drug Delivery Science and Technology
17 November 2025 in ChemRxiv
Glatiramer acetate (GA) electrostatically complexes with cytosine-guanine oligodeoxynucleotides (CpG ODN) forming ~100 nm cationic nanoparticles that localize this potent immunostimulant to the injection site. We previously reported GA-CpG nanoparticles retained the anti-tumor activity of CpG while mitigating systemic immune-related adverse events. Nonetheless, nanoparticulate systems like polypeptide-oligonucleotide complexes pose challenges with reproducible production, in-use stability, and storage stability which must be solved before translation for clinical use. In this study, we systematically investigated a microfluidic mixing process to define reproducible production of GA-CpG nanoparticles. Dynamic light scattering measurements revealed significantly smaller and more uniform nanoparticles for microfluidic processing versus traditional mixing via pipette. Next, we screened a range of buffer systems to determine the pH and ion types that could maintain colloidal stability and CpG potency. Buffer screening tests indicated that amino acid buffers, particularly glutamic acid, better maintained particle consistency than commonly used parenteral buffers. Finally, formulations of potential lyoprotectants and GA-CpG nanoparticles were developed. Freeze-thaw and freeze-drying experiments were conducted to assess the effects of buffers and lyoprotectants. Formulations with 5% HP-β-CD or trehalose yielded mean particle sizes of less than 127 nm and retained even after storage for 6 months at 40 °C/75% relative humidity. The work on electrostatic complexes reported here may provide valuable guidance to formulators aiming to optimize polypeptide-based oligonucleotide polyplex products.
17 October 2026 in Journal of Pharmaceutical Sciences
7 February 2026 in International Journal of Pharmaceutics